BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15645492)

  • 1. Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations.
    Fröhling S; Schlenk RF; Krauter J; Thiede C; Ehninger G; Haase D; Harder L; Kreitmeier S; Scholl C; Caligiuri MA; Bloomfield CD; Döhner H; Döhner K
    Genes Chromosomes Cancer; 2005 Apr; 42(4):427-32. PubMed ID: 15645492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia.
    Sweetser DA; Peniket AJ; Haaland C; Blomberg AA; Zhang Y; Zaidi ST; Dayyani F; Zhao Z; Heerema NA; Boultwood J; Dewald GW; Paietta E; Slovak ML; Willman CL; Wainscoat JS; Bernstein ID; Daly SB
    Genes Chromosomes Cancer; 2005 Nov; 44(3):279-91. PubMed ID: 16015647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
    Fröhling S; Schlenk RF; Stolze I; Bihlmayr J; Benner A; Kreitmeier S; Tobis K; Döhner H; Döhner K
    J Clin Oncol; 2004 Feb; 22(4):624-33. PubMed ID: 14726504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Del (9q) AML: clinical and cytological characteristics and prognostic implications.
    Peniket A; Wainscoat J; Side L; Daly S; Kusec R; Buck G; Wheatley K; Walker H; Chatters S; Harrison C; Boultwood J; Goldstone A; Burnett A
    Br J Haematol; 2005 Apr; 129(2):210-20. PubMed ID: 15813849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2.
    Snaddon J; Smith ML; Neat M; Cambal-Parrales M; Dixon-McIver A; Arch R; Amess JA; Rohatiner AZ; Lister TA; Fitzgibbon J
    Genes Chromosomes Cancer; 2003 May; 37(1):72-8. PubMed ID: 12661007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region.
    Naarmann-de Vries IS; Sackmann Y; Klein F; Ostareck-Lederer A; Ostareck DH; Jost E; Ehninger G; Brümmendorf TH; Marx G; Röllig C; Thiede C; Crysandt M
    Leuk Res; 2019 Jan; 76():15-23. PubMed ID: 30476680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4.
    Herold T; Metzeler KH; Vosberg S; Hartmann L; Jurinovic V; Opatz S; Konstandin NP; Schneider S; Zellmeier E; Ksienzyk B; Graf A; Krebs S; Blum H; Cristina Sauerland M; Büchner T; Berdel WE; Wörmann BJ; Mansmann U; Hiddemann W; Bohlander SK; Spiekermann K; Greif PA
    Genes Chromosomes Cancer; 2017 Jan; 56(1):75-86. PubMed ID: 27636548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.
    Pabst T; Eyholzer M; Haefliger S; Schardt J; Mueller BU
    J Clin Oncol; 2008 Nov; 26(31):5088-93. PubMed ID: 18768433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complexity of CEBPA dysregulation in human acute myeloid leukemia.
    Pabst T; Mueller BU
    Clin Cancer Res; 2009 Sep; 15(17):5303-7. PubMed ID: 19706798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution.
    Chou WC; Tang JL; Lin LI; Yao M; Tsay W; Chen CY; Wu SJ; Huang CF; Chiou RJ; Tseng MH; Lin DT; Lin KH; Chen YC; Tien HF
    Cancer Res; 2006 Mar; 66(6):3310-6. PubMed ID: 16540685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans.
    Larson RA; Le Beau MM
    Chem Biol Interact; 2005 May; 153-154():187-95. PubMed ID: 15935816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3.
    Smith ML; Arch R; Smith LL; Bainton N; Neat M; Taylor C; Bonnet D; Cavenagh JD; Andrew Lister T; Fitzgibbon J
    Br J Haematol; 2005 Feb; 128(3):318-23. PubMed ID: 15667533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML).
    Carnicer MJ; Lasa A; Buschbeck M; Serrano E; Carricondo M; Brunet S; Aventin A; Sierra J; Di Croce L; Nomdedeu JF
    Ann Hematol; 2008 Oct; 87(10):819-27. PubMed ID: 18587575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of RAS gene mutation and its cooperative genetic events in Southeast Asian adult acute myeloid leukemia.
    Auewarakul CU; Lauhakirti D; Tocharoentanaphol C
    Eur J Haematol; 2006 Jul; 77(1):51-6. PubMed ID: 16573741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia.
    Benthaus T; Schneider F; Mellert G; Zellmeier E; Schneider S; Kakadia PM; Hiddemann W; Bohlander SK; Feuring-Buske M; Braess J; Spiekermann K; Dufour A
    Br J Haematol; 2008 Oct; 143(2):230-9. PubMed ID: 18752591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.
    Renneville A; Boissel N; Zurawski V; Llopis L; Biggio V; Nibourel O; Philippe N; Thomas X; Dombret H; Preudhomme C
    Cancer; 2009 Aug; 115(16):3719-27. PubMed ID: 19536888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO.
    Kuchenbauer F; Schnittger S; Look T; Gilliland G; Tenen D; Haferlach T; Hiddemann W; Buske C; Schoch C
    Br J Haematol; 2006 Sep; 134(6):616-9. PubMed ID: 16938118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of del(20q) in patients with hematological malignancies.
    Brezinová J; Zemanová Z; Ransdorfová S; Sindelárová L; Sisková M; Neuwirtová R; Cermák J; Michalová K
    Cancer Genet Cytogenet; 2005 Jul; 160(2):188-92. PubMed ID: 15993278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma.
    Fuchs O; Provaznikova D; Kocova M; Kostecka A; Cvekova P; Neuwirtova R; Kobylka P; Cermak J; Brezinova J; Schwarz J; Markova J; Salaj P; Klamova H; Maaloufova J; Lemez P; Novakova L; Benesova K
    Blood Cells Mol Dis; 2008; 40(3):401-5. PubMed ID: 18182175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.